Share Price and Basic Stock Data
Last Updated: January 17, 2026, 7:03 am
| PEG Ratio | 13.28 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Hester Biosciences Ltd, a prominent player in the pharmaceuticals sector, reported a share price of ₹1,529 and a market capitalization of ₹1,300 Cr. The company has shown a consistent upward trend in revenue, with sales increasing from ₹235 Cr in March 2022 to ₹266 Cr in March 2023, and projected to reach ₹311 Cr by March 2025. The trailing twelve months (TTM) revenue stands at ₹300 Cr, indicating stable growth. Quarterly sales figures reflect seasonal variations, with the highest sales recorded at ₹88 Cr in June 2023, followed by a decline to ₹70 Cr in September 2023. This fluctuation suggests a need for strategic planning to manage demand effectively. The overall sales growth from previous years highlights Hester’s ability to capture market share and expand its product offerings, which is crucial in the competitive pharmaceuticals landscape.
Profitability and Efficiency Metrics
Hester Biosciences reported a net profit of ₹45 Cr for the latest fiscal year, with a net profit margin of 7.94% for March 2025, reflecting an improvement from 5.43% in March 2024. The operating profit margin (OPM) stood at 20.88%, showcasing effective cost management despite rising operational expenses, which reached ₹250 Cr in March 2025. The company’s return on equity (ROE) is relatively modest at 9.18%, while return on capital employed (ROCE) is slightly higher at 9.71%. Notably, the interest coverage ratio (ICR) of 5.12x indicates a healthy capacity to service debt, providing reassurance to stakeholders about financial stability. However, the cash conversion cycle (CCC) of 255 days raises concerns regarding operational efficiency, particularly in inventory management, which could hinder cash flow if not addressed promptly.
Balance Sheet Strength and Financial Ratios
Hester’s balance sheet reflects a total equity of ₹329 Cr, with borrowings amounting to ₹214 Cr, resulting in a debt-to-equity ratio of 0.66x. This level of leverage is manageable but suggests the company is utilizing debt to finance its growth, which should be monitored closely. The book value per share has increased to ₹369.41 as of March 2025, indicating a positive trend in shareholder equity. The current ratio of 1.56x suggests that Hester can comfortably meet its short-term obligations, although the quick ratio of 0.99x indicates potential liquidity challenges. The price-to-book value (P/BV) ratio stands at 3.39x, which is within typical sector ranges, signalling that the stock is reasonably valued in relation to its book value. Overall, the financial ratios suggest a solid foundation but also highlight areas for improvement, particularly in liquidity management.
Shareholding Pattern and Investor Confidence
As of September 2025, Hester Biosciences’ shareholding pattern reveals a strong promoter holding of 53.73%, indicating substantial insider confidence in the company’s future. Foreign institutional investors (FIIs) account for a small 0.53% stake, while domestic institutional investors (DIIs) have not invested significantly, holding 0%. The public holds 45.73% of the shares, amounting to 12,260 shareholders, which demonstrates a healthy level of retail interest. The fluctuation in the number of shareholders over recent quarters, particularly a decline from 13,391 in December 2022 to 12,260 in September 2025, may raise concerns about investor sentiment. However, the high promoter stake could mitigate these concerns, suggesting that insiders are aligned with long-term growth strategies and are committed to maintaining shareholder value.
Outlook, Risks, and Final Insight
Hester Biosciences faces a mixed outlook, with strengths such as a solid sales growth trajectory and a manageable debt level, coupled with risks associated with operational inefficiencies and a declining number of shareholders. The company must focus on improving its cash conversion cycle and inventory management to enhance liquidity and operational efficiency. Additionally, the low institutional investment may limit the stock’s volatility and appeal to larger investors. As the company continues to innovate and expand its product lines, particularly in the growing pharmaceuticals sector, its ability to adapt to market demands will be crucial. If Hester can address its operational challenges while maintaining its growth momentum, it could strengthen its market position and enhance shareholder value in the long run. Conversely, failure to manage these risks could impact profitability and investor confidence significantly.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 127 Cr. | 101 | 205/84.3 | 28.1 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,910 Cr. | 356 | 479/192 | 81.0 | 24.3 | 0.19 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.1 Cr. | 45.9 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.4 Cr. | 39.9 | 41.0/17.0 | 139 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,986.51 Cr | 1,115.90 | 52.25 | 202.18 | 0.37% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 73 | 75 | 67 | 88 | 70 | 67 | 79 | 82 | 84 | 63 | 82 | 84 | 71 |
| Expenses | 60 | 56 | 56 | 73 | 57 | 57 | 63 | 65 | 65 | 58 | 63 | 61 | 59 |
| Operating Profit | 13 | 19 | 12 | 14 | 13 | 10 | 16 | 18 | 19 | 5 | 19 | 23 | 12 |
| OPM % | 17% | 25% | 17% | 16% | 19% | 15% | 20% | 21% | 23% | 8% | 23% | 27% | 17% |
| Other Income | 5 | 6 | 3 | 3 | 6 | 2 | 5 | 2 | 3 | 9 | -6 | 3 | 12 |
| Interest | 2 | 4 | 1 | 3 | 8 | 2 | 7 | 5 | 6 | -4 | 6 | 2 | 2 |
| Depreciation | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Profit before tax | 10 | 16 | 8 | 9 | 7 | 6 | 10 | 11 | 12 | 13 | 4 | 20 | 17 |
| Tax % | 36% | 24% | 32% | 25% | 40% | 37% | 35% | 29% | 29% | 15% | 59% | 14% | 16% |
| Net Profit | 7 | 12 | 6 | 7 | 4 | 4 | 6 | 7 | 8 | 11 | 2 | 17 | 14 |
| EPS in Rs | 8.16 | 13.15 | 5.33 | 6.90 | 4.81 | 4.68 | 5.82 | 7.45 | 9.64 | 13.71 | 1.52 | 19.33 | 16.99 |
Last Updated: January 1, 2026, 11:46 am
Below is a detailed analysis of the quarterly data for Hester Biosciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 71.00 Cr.. The value appears to be declining and may need further review. It has decreased from 84.00 Cr. (Jun 2025) to 71.00 Cr., marking a decrease of 13.00 Cr..
- For Expenses, as of Sep 2025, the value is 59.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 61.00 Cr. (Jun 2025) to 59.00 Cr., marking a decrease of 2.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 12.00 Cr.. The value appears to be declining and may need further review. It has decreased from 23.00 Cr. (Jun 2025) to 12.00 Cr., marking a decrease of 11.00 Cr..
- For OPM %, as of Sep 2025, the value is 17.00%. The value appears to be declining and may need further review. It has decreased from 27.00% (Jun 2025) to 17.00%, marking a decrease of 10.00%.
- For Other Income, as of Sep 2025, the value is 12.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Jun 2025) to 12.00 Cr., marking an increase of 9.00 Cr..
- For Interest, as of Sep 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 2.00 Cr..
- For Depreciation, as of Sep 2025, the value is 4.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 4.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 17.00 Cr.. The value appears to be declining and may need further review. It has decreased from 20.00 Cr. (Jun 2025) to 17.00 Cr., marking a decrease of 3.00 Cr..
- For Tax %, as of Sep 2025, the value is 16.00%. The value appears to be increasing, which may not be favorable. It has increased from 14.00% (Jun 2025) to 16.00%, marking an increase of 2.00%.
- For Net Profit, as of Sep 2025, the value is 14.00 Cr.. The value appears to be declining and may need further review. It has decreased from 17.00 Cr. (Jun 2025) to 14.00 Cr., marking a decrease of 3.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 16.99. The value appears to be declining and may need further review. It has decreased from 19.33 (Jun 2025) to 16.99, marking a decrease of 2.34.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:16 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 69 | 90 | 101 | 123 | 136 | 178 | 183 | 214 | 235 | 266 | 305 | 311 | 300 |
| Expenses | 44 | 64 | 67 | 82 | 89 | 110 | 128 | 146 | 175 | 215 | 251 | 250 | 241 |
| Operating Profit | 24 | 25 | 34 | 41 | 47 | 68 | 55 | 69 | 60 | 51 | 54 | 62 | 59 |
| OPM % | 36% | 28% | 34% | 33% | 35% | 38% | 30% | 32% | 26% | 19% | 18% | 20% | 20% |
| Other Income | 1 | 3 | 1 | 0 | 3 | 7 | 6 | 1 | 14 | 20 | 15 | 8 | 18 |
| Interest | 6 | 5 | 4 | 4 | 4 | 7 | 7 | 7 | 4 | 9 | 20 | 13 | 6 |
| Depreciation | 5 | 6 | 6 | 7 | 10 | 12 | 13 | 13 | 17 | 21 | 17 | 17 | 17 |
| Profit before tax | 13 | 18 | 25 | 31 | 36 | 57 | 41 | 50 | 54 | 40 | 32 | 40 | 54 |
| Tax % | 31% | 26% | 23% | 26% | 36% | 28% | 25% | 31% | 26% | 30% | 34% | 27% | |
| Net Profit | 9 | 13 | 19 | 23 | 23 | 41 | 31 | 35 | 39 | 28 | 21 | 29 | 45 |
| EPS in Rs | 11.11 | 15.99 | 22.57 | 27.68 | 30.12 | 48.87 | 34.29 | 40.47 | 46.22 | 31.30 | 22.21 | 32.31 | 51.55 |
| Dividend Payout % | 18% | 19% | 18% | 19% | 33% | 23% | 19% | 25% | 22% | 26% | 27% | 22% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 44.44% | 46.15% | 21.05% | 0.00% | 78.26% | -24.39% | 12.90% | 11.43% | -28.21% | -25.00% | 38.10% |
| Change in YoY Net Profit Growth (%) | 0.00% | 1.71% | -25.10% | -21.05% | 78.26% | -102.65% | 37.29% | -1.47% | -39.63% | 3.21% | 63.10% |
Hester Biosciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 11% |
| 3 Years: | 10% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | -1% |
| 3 Years: | -11% |
| TTM: | 94% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 6% |
| 3 Years: | 0% |
| 1 Year: | -15% |
| Return on Equity | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 11% |
| 3 Years: | 9% |
| Last Year: | 9% |
Last Updated: September 5, 2025, 6:05 am
Balance Sheet
Last Updated: December 4, 2025, 1:21 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
| Reserves | 66 | 76 | 93 | 113 | 132 | 169 | 193 | 220 | 251 | 271 | 283 | 306 | 329 |
| Borrowings | 48 | 55 | 59 | 66 | 69 | 90 | 121 | 110 | 228 | 274 | 244 | 213 | 214 |
| Other Liabilities | 19 | 20 | 25 | 25 | 35 | 32 | 65 | 73 | 74 | 116 | 126 | 126 | 124 |
| Total Liabilities | 142 | 160 | 186 | 213 | 244 | 299 | 387 | 411 | 562 | 670 | 662 | 653 | 675 |
| Fixed Assets | 54 | 60 | 65 | 102 | 110 | 145 | 142 | 133 | 237 | 259 | 240 | 233 | 247 |
| CWIP | 21 | 33 | 36 | 21 | 32 | 7 | 74 | 109 | 82 | 149 | 171 | 183 | 182 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 21 | 25 | 30 | 34 | 37 |
| Other Assets | 68 | 68 | 85 | 89 | 102 | 148 | 170 | 169 | 222 | 237 | 221 | 203 | 209 |
| Total Assets | 142 | 160 | 186 | 213 | 244 | 299 | 387 | 411 | 562 | 670 | 662 | 653 | 675 |
Below is a detailed analysis of the balance sheet data for Hester Biosciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 9.00 Cr..
- For Reserves, as of Sep 2025, the value is 329.00 Cr.. The value appears strong and on an upward trend. It has increased from 306.00 Cr. (Mar 2025) to 329.00 Cr., marking an increase of 23.00 Cr..
- For Borrowings, as of Sep 2025, the value is 214.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 213.00 Cr. (Mar 2025) to 214.00 Cr., marking an increase of 1.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 124.00 Cr.. The value appears to be improving (decreasing). It has decreased from 126.00 Cr. (Mar 2025) to 124.00 Cr., marking a decrease of 2.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 675.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 653.00 Cr. (Mar 2025) to 675.00 Cr., marking an increase of 22.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 247.00 Cr.. The value appears strong and on an upward trend. It has increased from 233.00 Cr. (Mar 2025) to 247.00 Cr., marking an increase of 14.00 Cr..
- For CWIP, as of Sep 2025, the value is 182.00 Cr.. The value appears to be declining and may need further review. It has decreased from 183.00 Cr. (Mar 2025) to 182.00 Cr., marking a decrease of 1.00 Cr..
- For Investments, as of Sep 2025, the value is 37.00 Cr.. The value appears strong and on an upward trend. It has increased from 34.00 Cr. (Mar 2025) to 37.00 Cr., marking an increase of 3.00 Cr..
- For Other Assets, as of Sep 2025, the value is 209.00 Cr.. The value appears strong and on an upward trend. It has increased from 203.00 Cr. (Mar 2025) to 209.00 Cr., marking an increase of 6.00 Cr..
- For Total Assets, as of Sep 2025, the value is 675.00 Cr.. The value appears strong and on an upward trend. It has increased from 653.00 Cr. (Mar 2025) to 675.00 Cr., marking an increase of 22.00 Cr..
Notably, the Reserves (329.00 Cr.) exceed the Borrowings (214.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -24.00 | -30.00 | -25.00 | -25.00 | -22.00 | -22.00 | -66.00 | -41.00 | -168.00 | -223.00 | -190.00 | -151.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 75 | 72 | 95 | 79 | 87 | 67 | 116 | 84 | 86 | 109 | 94 | 86 |
| Inventory Days | 1,145 | 431 | 627 | 376 | 505 | 540 | 834 | 452 | 424 | 399 | 288 | 291 |
| Days Payable | 145 | 68 | 109 | 84 | 100 | 93 | 261 | 204 | 101 | 141 | 98 | 122 |
| Cash Conversion Cycle | 1,074 | 434 | 614 | 371 | 491 | 514 | 690 | 332 | 409 | 367 | 284 | 255 |
| Working Capital Days | 36 | 76 | 112 | 90 | 82 | 106 | 104 | 134 | 113 | 88 | 112 | 74 |
| ROCE % | 18% | 15% | 19% | 19% | 20% | 26% | 16% | 18% | 14% | 9% | 9% | 10% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF | 41 | 0.08 | 0.01 | 41 | 2025-04-22 17:25:33 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 33.89 | 24.88 | 32.96 | 46.41 | 40.79 |
| Diluted EPS (Rs.) | 33.89 | 24.88 | 32.96 | 46.41 | 40.79 |
| Cash EPS (Rs.) | 48.82 | 39.65 | 52.10 | 65.41 | 56.44 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 369.41 | 356.03 | 339.19 | 314.32 | 277.37 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 369.41 | 356.03 | 339.19 | 314.32 | 277.37 |
| Revenue From Operations / Share (Rs.) | 365.70 | 357.99 | 312.79 | 276.25 | 251.95 |
| PBDIT / Share (Rs.) | 76.38 | 75.58 | 77.30 | 86.66 | 86.21 |
| PBIT / Share (Rs.) | 56.63 | 55.39 | 52.97 | 67.17 | 70.56 |
| PBT / Share (Rs.) | 41.70 | 32.14 | 42.02 | 62.39 | 58.90 |
| Net Profit / Share (Rs.) | 29.07 | 19.46 | 27.77 | 45.92 | 40.79 |
| NP After MI And SOA / Share (Rs.) | 32.31 | 22.20 | 31.30 | 46.41 | 40.47 |
| PBDIT Margin (%) | 20.88 | 21.11 | 24.71 | 31.37 | 34.21 |
| PBIT Margin (%) | 15.48 | 15.47 | 16.93 | 24.31 | 28.00 |
| PBT Margin (%) | 11.40 | 8.97 | 13.43 | 22.58 | 23.37 |
| Net Profit Margin (%) | 7.94 | 5.43 | 8.87 | 16.62 | 16.18 |
| NP After MI And SOA Margin (%) | 8.83 | 6.20 | 10.00 | 16.80 | 16.06 |
| Return on Networth / Equity (%) | 8.74 | 6.47 | 9.51 | 15.18 | 15.08 |
| Return on Capital Employeed (%) | 9.12 | 8.46 | 8.64 | 12.28 | 17.16 |
| Return On Assets (%) | 4.20 | 2.85 | 3.97 | 7.02 | 8.37 |
| Long Term Debt / Equity (X) | 0.42 | 0.62 | 0.66 | 0.63 | 0.36 |
| Total Debt / Equity (X) | 0.66 | 0.81 | 0.95 | 0.85 | 0.37 |
| Asset Turnover Ratio (%) | 0.47 | 0.45 | 0.43 | 0.52 | 0.62 |
| Current Ratio (X) | 1.56 | 2.03 | 1.53 | 2.01 | 2.63 |
| Quick Ratio (X) | 0.99 | 1.31 | 0.96 | 1.23 | 1.62 |
| Inventory Turnover Ratio (X) | 4.26 | 0.67 | 0.66 | 0.52 | 0.39 |
| Dividend Payout Ratio (NP) (%) | 18.56 | 36.02 | 31.94 | 21.54 | 16.30 |
| Dividend Payout Ratio (CP) (%) | 11.52 | 18.86 | 17.97 | 15.17 | 11.76 |
| Earning Retention Ratio (%) | 81.44 | 63.98 | 68.06 | 78.46 | 83.70 |
| Cash Earning Retention Ratio (%) | 88.48 | 81.14 | 82.03 | 84.83 | 88.24 |
| Interest Coverage Ratio (X) | 5.12 | 3.25 | 7.06 | 18.14 | 11.11 |
| Interest Coverage Ratio (Post Tax) (X) | 2.95 | 1.84 | 3.53 | 10.61 | 6.76 |
| Enterprise Value (Cr.) | 1279.65 | 1416.65 | 1555.60 | 2514.68 | 1703.08 |
| EV / Net Operating Revenue (X) | 4.11 | 4.65 | 5.85 | 10.70 | 7.95 |
| EV / EBITDA (X) | 19.69 | 22.03 | 23.66 | 34.11 | 23.22 |
| MarketCap / Net Operating Revenue (X) | 3.43 | 3.88 | 4.86 | 9.83 | 7.61 |
| Retention Ratios (%) | 81.43 | 63.97 | 68.05 | 78.45 | 83.69 |
| Price / BV (X) | 3.39 | 4.05 | 4.62 | 8.88 | 7.14 |
| Price / Net Operating Revenue (X) | 3.43 | 3.88 | 4.86 | 9.83 | 7.61 |
| EarningsYield | 0.02 | 0.01 | 0.02 | 0.01 | 0.02 |
After reviewing the key financial ratios for Hester Biosciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 33.89. This value is within the healthy range. It has increased from 24.88 (Mar 24) to 33.89, marking an increase of 9.01.
- For Diluted EPS (Rs.), as of Mar 25, the value is 33.89. This value is within the healthy range. It has increased from 24.88 (Mar 24) to 33.89, marking an increase of 9.01.
- For Cash EPS (Rs.), as of Mar 25, the value is 48.82. This value is within the healthy range. It has increased from 39.65 (Mar 24) to 48.82, marking an increase of 9.17.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 369.41. It has increased from 356.03 (Mar 24) to 369.41, marking an increase of 13.38.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 369.41. It has increased from 356.03 (Mar 24) to 369.41, marking an increase of 13.38.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 365.70. It has increased from 357.99 (Mar 24) to 365.70, marking an increase of 7.71.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 76.38. This value is within the healthy range. It has increased from 75.58 (Mar 24) to 76.38, marking an increase of 0.80.
- For PBIT / Share (Rs.), as of Mar 25, the value is 56.63. This value is within the healthy range. It has increased from 55.39 (Mar 24) to 56.63, marking an increase of 1.24.
- For PBT / Share (Rs.), as of Mar 25, the value is 41.70. This value is within the healthy range. It has increased from 32.14 (Mar 24) to 41.70, marking an increase of 9.56.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 29.07. This value is within the healthy range. It has increased from 19.46 (Mar 24) to 29.07, marking an increase of 9.61.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 32.31. This value is within the healthy range. It has increased from 22.20 (Mar 24) to 32.31, marking an increase of 10.11.
- For PBDIT Margin (%), as of Mar 25, the value is 20.88. This value is within the healthy range. It has decreased from 21.11 (Mar 24) to 20.88, marking a decrease of 0.23.
- For PBIT Margin (%), as of Mar 25, the value is 15.48. This value is within the healthy range. It has increased from 15.47 (Mar 24) to 15.48, marking an increase of 0.01.
- For PBT Margin (%), as of Mar 25, the value is 11.40. This value is within the healthy range. It has increased from 8.97 (Mar 24) to 11.40, marking an increase of 2.43.
- For Net Profit Margin (%), as of Mar 25, the value is 7.94. This value is within the healthy range. It has increased from 5.43 (Mar 24) to 7.94, marking an increase of 2.51.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 8.83. This value is within the healthy range. It has increased from 6.20 (Mar 24) to 8.83, marking an increase of 2.63.
- For Return on Networth / Equity (%), as of Mar 25, the value is 8.74. This value is below the healthy minimum of 15. It has increased from 6.47 (Mar 24) to 8.74, marking an increase of 2.27.
- For Return on Capital Employeed (%), as of Mar 25, the value is 9.12. This value is below the healthy minimum of 10. It has increased from 8.46 (Mar 24) to 9.12, marking an increase of 0.66.
- For Return On Assets (%), as of Mar 25, the value is 4.20. This value is below the healthy minimum of 5. It has increased from 2.85 (Mar 24) to 4.20, marking an increase of 1.35.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.42. This value is within the healthy range. It has decreased from 0.62 (Mar 24) to 0.42, marking a decrease of 0.20.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.66. This value is within the healthy range. It has decreased from 0.81 (Mar 24) to 0.66, marking a decrease of 0.15.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.47. It has increased from 0.45 (Mar 24) to 0.47, marking an increase of 0.02.
- For Current Ratio (X), as of Mar 25, the value is 1.56. This value is within the healthy range. It has decreased from 2.03 (Mar 24) to 1.56, marking a decrease of 0.47.
- For Quick Ratio (X), as of Mar 25, the value is 0.99. This value is below the healthy minimum of 1. It has decreased from 1.31 (Mar 24) to 0.99, marking a decrease of 0.32.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.26. This value is within the healthy range. It has increased from 0.67 (Mar 24) to 4.26, marking an increase of 3.59.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 18.56. This value is below the healthy minimum of 20. It has decreased from 36.02 (Mar 24) to 18.56, marking a decrease of 17.46.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 11.52. This value is below the healthy minimum of 20. It has decreased from 18.86 (Mar 24) to 11.52, marking a decrease of 7.34.
- For Earning Retention Ratio (%), as of Mar 25, the value is 81.44. This value exceeds the healthy maximum of 70. It has increased from 63.98 (Mar 24) to 81.44, marking an increase of 17.46.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 88.48. This value exceeds the healthy maximum of 70. It has increased from 81.14 (Mar 24) to 88.48, marking an increase of 7.34.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.12. This value is within the healthy range. It has increased from 3.25 (Mar 24) to 5.12, marking an increase of 1.87.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.95. This value is below the healthy minimum of 3. It has increased from 1.84 (Mar 24) to 2.95, marking an increase of 1.11.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,279.65. It has decreased from 1,416.65 (Mar 24) to 1,279.65, marking a decrease of 137.00.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.11. This value exceeds the healthy maximum of 3. It has decreased from 4.65 (Mar 24) to 4.11, marking a decrease of 0.54.
- For EV / EBITDA (X), as of Mar 25, the value is 19.69. This value exceeds the healthy maximum of 15. It has decreased from 22.03 (Mar 24) to 19.69, marking a decrease of 2.34.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.43. This value exceeds the healthy maximum of 3. It has decreased from 3.88 (Mar 24) to 3.43, marking a decrease of 0.45.
- For Retention Ratios (%), as of Mar 25, the value is 81.43. This value exceeds the healthy maximum of 70. It has increased from 63.97 (Mar 24) to 81.43, marking an increase of 17.46.
- For Price / BV (X), as of Mar 25, the value is 3.39. This value exceeds the healthy maximum of 3. It has decreased from 4.05 (Mar 24) to 3.39, marking a decrease of 0.66.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.43. This value exceeds the healthy maximum of 3. It has decreased from 3.88 (Mar 24) to 3.43, marking a decrease of 0.45.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Hester Biosciences Ltd:
- Net Profit Margin: 7.94%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 9.12% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 8.74% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.95
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.99
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 29.3 (Industry average Stock P/E: 52.25)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.66
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 7.94%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | �Pushpak� 1st Floor, Panchvati Circle, Ahmedabad Gujarat 380006 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Bhupendra Gandhi | Chairman |
| Mr. Rajiv Gandhi | Managing Director & CEO |
| Ms. Priya Gandhi | Executive Director |
| Mr. Ravin Gandhi | Director |
| Mr. Sanjiv Gandhi | Director |
| Mr. Ashok Bhadakal | Independent Director |
| Ms. Sandhya Patel | Independent Director |
| Mr. Ameet Desai | Independent Director |
| Mr. Anil Jain | Independent Director |
| Mr. Jatin Trivedi | Independent Director |
| Ms. Nina Gandhi | Alternate Director |
FAQ
What is the intrinsic value of Hester Biosciences Ltd?
Hester Biosciences Ltd's intrinsic value (as of 18 January 2026) is ₹877.13 which is 41.91% lower the current market price of ₹1,510.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹1,285 Cr. market cap, FY2025-2026 high/low of ₹2,350/1,243, reserves of ₹329 Cr, and liabilities of ₹675 Cr.
What is the Market Cap of Hester Biosciences Ltd?
The Market Cap of Hester Biosciences Ltd is 1,285 Cr..
What is the current Stock Price of Hester Biosciences Ltd as on 18 January 2026?
The current stock price of Hester Biosciences Ltd as on 18 January 2026 is ₹1,510.
What is the High / Low of Hester Biosciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Hester Biosciences Ltd stocks is ₹2,350/1,243.
What is the Stock P/E of Hester Biosciences Ltd?
The Stock P/E of Hester Biosciences Ltd is 29.3.
What is the Book Value of Hester Biosciences Ltd?
The Book Value of Hester Biosciences Ltd is 397.
What is the Dividend Yield of Hester Biosciences Ltd?
The Dividend Yield of Hester Biosciences Ltd is 0.46 %.
What is the ROCE of Hester Biosciences Ltd?
The ROCE of Hester Biosciences Ltd is 9.71 %.
What is the ROE of Hester Biosciences Ltd?
The ROE of Hester Biosciences Ltd is 9.18 %.
What is the Face Value of Hester Biosciences Ltd?
The Face Value of Hester Biosciences Ltd is 10.0.